Prelude Therapeutics Inc — Director's Dealing 2021

Dec 17, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Prelude Therapeutics Inc (PRLD)
CIK: 0001678660
Period of Report: 2021-12-15

Reporting Person: Morosini Deborah (EVP, Chief of Clinical Affairs)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-12-15	Common Stock	M	3016	$1.89	Acquired	3460	Direct
2021-12-15	Common Stock	M	25735	$12.85	Acquired	29195	Direct
2021-12-15	Common Stock	S	28751	$13.00	Disposed	444	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-12-15	Employee Stock Option (right to buy)	$1.89	M	3016	Disposed	2030-03-26	Common Stock (3016)	Direct
2021-12-15	Employee Stock Option (right to buy)	$12.85	M	24853	Disposed	2030-09-01	Common Stock (24853)	Direct
2021-12-15	Employee Stock Option (right to buy)	$12.85	M	882	Disposed	2030-09-01	Common Stock (882)	Direct

Footnotes

F1: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F2: The stock option is fully vested.

F3: The stock option vests as to 25% of the total shares monthly beginning on September 24, 2021, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on the vesting date.

F4: The stock option vests as to 25% of the total shares monthly beginning on July 27, 2020, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on the vesting date.